JPMorgan Chase & Co. reiterated their overweight rating on shares of Reckitt Benckiser Group (LON:RB) in a research note released on Monday, Marketbeat Ratings reports. The brokerage currently has a GBX 9,000 ($117.60) price target on the stock.
A number of other brokerages have also recently commented on RB. UBS Group reaffirmed a neutral rating and issued a GBX 6,300 ($82.32) price target (down from GBX 6,400 ($83.63)) on shares of Reckitt Benckiser Group in a research note on Friday, October 26th. Credit Suisse Group upped their price target on Reckitt Benckiser Group from GBX 5,950 ($77.75) to GBX 6,000 ($78.40) and gave the company an underperform rating in a research note on Friday, November 23rd. BNP Paribas raised Reckitt Benckiser Group to an outperform rating and upped their price target for the company from GBX 6,800 ($88.85) to GBX 7,500 ($98.00) in a research note on Tuesday, November 20th. Morgan Stanley reissued a buy rating on shares of Reckitt Benckiser Group in a research note on Tuesday, October 16th. Finally, Liberum Capital reissued a buy rating on shares of Reckitt Benckiser Group in a research note on Friday, October 19th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of GBX 6,871.67 ($89.79).
Shares of RB stock opened at GBX 6,090 ($79.58) on Monday. Reckitt Benckiser Group has a one year low of GBX 5,562 ($72.68) and a one year high of GBX 8,110.43 ($105.98).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Read More: Stop Order
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.